Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel
1.04K subscribers
136 photos
55 videos
2 files
2.51K links
NVIDIA inception Member, Nebius AI Discovery Awards semifinalist

Potentially first $1T Longevity BioTech AI company

Part of Longevity Ecosystem
LongevityInTime.com

@PickleballPartners

Shop
https://web.tribute.tg/l/lr

Homes
www.Africa.Villas
Download Telegram
3D-Printed Soft Implant Cools Brain to Stop Seizures

Originally designed to treat epilepsy, a 3D-printed silicone chip with microelectrodes and microfluidic channels monitors cortical activity and suppresses seizures through local tissue cooling.

Beyond epilepsy, the technology holds potential for thermal management of neural implants. Any brain surgery — including neurointerface insertion — hits a hard thermodynamic wall: the brain evolved for a modest 20 watts and lacks natural radiators. Pushing neural circuits harder causes local overheating, denaturing proteins and degrading tissue.

Such microfluidic implants could act as heat sinks for living nervous systems. Instead of blunt pharmacology or permanent electrical ablation, they offer a mechanism for reversible inhibition — damping overload during peak cognitive tasks, cooling overheated circuits, or blocking stress noise. Advanced Science, 2025

🔗 Read original →
Montana ETRB Conditionally Approves First Experimental Treatment Protocol

On August 26, Montana's Experimental Treatment Review Board (ETRB) unanimously approved, with conditions, an application from Parley Neurotech. This marks the first decision under Montana law SB 535, which licenses clinics and requires reporting, while the private ETRB reviews specific protocols before patient treatment. In July, Infinita launched the ETRB and began accepting applications; letter RDL-2026-001 now records the first ruling.

SB 535 permits interventions after Phase 1 clinical trials. The state licenses the treatment center and receives serious adverse event reports. The private ETRB evaluates patient consent, alternatives, safety, and the risk-benefit ratio for each protocol.

Parley proposed a four-week course combining the antihistamine clemastine and specially tuned audio delivered via headphones for age-related auditory processing decline. The board mandated rewriting the informed consent, preserving physician discretion to order ECGs, exams, and lab tests, and assessing risks to the heart, kidneys, liver, blood markers, and fall risk. Once written confirmation of these conditions is met, the protocol may proceed only at the state-licensed center that appointed this ETRB.

The same protocol is listed on ClinicalTrials.gov as a recruiting randomized, double-blind Phase 1/2a study with four arms, where participants, clinicians, investigators, and outcome assessors are all blinded.

Business Insider reports the ETRB is managed by private company Infinita City. Board Chair Matt Kaeberlein also sits on the board of the Alliance for Longevity Initiatives (A4LI); per the outlet, A4LI and Infinita founder Niklas Anzinger helped draft SB 535. Montana rules prohibit ETRB members from holding personal, financial, employment, or property interests in the centers they oversee; the RDL notes members confirmed conflict-of-interest declarations at the meeting.

🔗 Read original →
Caloric restriction effects vary widely across mouse strains and sexes

In a 2010 study, researchers tested a single 40% caloric restriction dose across 41 genetically distinct mouse lines of both sexes. A statistically significant lifespan increase appeared in only 5% of male lines and 21% of female lines, while lifespan decreased in 27% of males and 26% of females. The authors explicitly noted that whether non-responding lines would benefit from a milder restriction "remains to be established."

On September 15, biomedical researcher Avi Roy revisited this question, emphasizing that "useful for all" remains an assumption until a full panel is tested across multiple restriction levels.

A 2021 replication selected the four lines showing the strongest lifespan reductions in the original study and expanded group sizes from 5 to 30–45 mice. Seven of eight original results failed to replicate. In line 107, female median lifespan rose 24% while male lifespan fell 22%.

A 2024 study of 937 genetically diverse females across five dietary regimens found a ~36% median lifespan increase at 40% restriction. Genetics accounted for 23.6% of lifespan variance, diet for only 7.4%.

These population averages and strain-specific responses answer different questions. Designing a regimen for the full 41-line panel requires a new experiment testing multiple restriction levels in both sexes.

🔗 Read original →
Enveda Launches CASMI 2026 Challenge for Molecular Structure Identification

On September 14, biotech company Enveda launched CASMI 2026 on Kaggle, a competition to determine the structure of small molecules from tandem mass spectra. The prize pool is $50,000; submissions are accepted until December 14.

A mass spectrometer ionizes a molecule, fragments it, and measures the mass-to-charge ratios. Researchers use these signals to reconstruct atomic connectivity. When analyzing biological samples, they see thousands of signals, yet the structure of roughly 90% of small molecules remains unknown, according to C&EN. These unidentified compounds are known as the dark metabolome.

CASMI was created in 2012 to benchmark identification methods on a common dataset. Organizers verify structures beforehand, while participants receive only the spectra. Enveda has now adapted this framework into an open machine-learning challenge. The company provided spectra of purified natural products for training and standardized public datasets into a single format. The hidden test set contains spectra of molecules absent from public databases.

Under CASMI 2026 rules, algorithms propose up to 25 candidate 2D structures per spectrum. The MRR@25 metric rewards models that rank the correct structure higher. The hidden set ensures blind evaluation on a single shared task.

Oliver Fiehn, a computational chemist at UC Davis who ran CASMI in 2022, noted the focus on isolated compounds: "They concentrated on mass spectra of isolated compounds — and that by itself is hard enough." In real biological samples, overlapping signals and adduct formation complicate analysis; using purified compounds isolates the core structure-spectrum mapping problem.

🔗 Read original →
Patrick Mineault Breaks Down Viral "Fly Connectome" Demos: Biological Models Need Testable Predictions

On September 14, neuroscientist and AI researcher Patrick Mineault analyzed viral videos showing a fruit fly connectome playing *Beat Saber*, *Doom*, and *Minecraft*. The on-screen movement depends entirely on how the neural wiring diagram is converted into a network and linked to a controller or virtual body.

A model's biological validity is tested by whether its inputs and outputs match real measurements and whether it yields testable predictions. A connectome maps synaptic connections between neurons. The MaleCNS dataset provides a complete map of the male *Drosophila* central nervous system, including the ventral nerve cord linking brain to body. The map shows *which* neurons connect; simulating their dynamics requires firing thresholds, synaptic weights, and delays.

One approach uses a Leaky Integrate-and-Fire (LIF) network: neurons sum inputs and spike upon reaching a threshold. In one demo Mineault reviewed, the network received random input, and spikes from a few neurons were mapped directly to button presses. In a March demo by Eon, several output neurons sent "walk forward" and "turn" commands to a virtual body, while pre-built motor controllers coordinated the legs.

Philip Shiu and colleagues applied a whole-brain LIF model to a narrower question: which neurons activate after taste or mechanosensory signals? They then used optogenetics to activate those specific neurons in real flies and observed behavior. Thus, the wiring diagram generated testable predictions for feeding and grooming circuits.

Bingni Brunton and colleagues ran a critical control: they connected the *C. elegans* connectome to a physical fly body model. A separate neural network, trained via reinforcement learning, translated worm neuron activity into commands for 42 actuators across six legs; the simulation produced a realistic gait. "Plausible behavior can emerge without biological fidelity."

Jan Lappalainen and co-authors took the fly visual system structure, fit model parameters to motion estimation, and validated neural activity predictions against data from 26 studies. For a whole-fly model, Mineault proposes linking visual signals, motor commands, and proprioceptive feedback to empirical measurements, then validating the model against natural behavior and physiology.

🔗 Read original →
Authors urge early oversight framework for long-term donor organ storage

Avi Roy highlighted a regulatory gap on September 13, 2026: FDA rules for human cells, tissues, and cellular and tissue-based products (HCT/Ps) explicitly exclude vascularized organs. The closest FDA precedent covers a device that prepares a liver for transplant — not an organ after extended storage.

Currently, donor organs are cooled and transplanted quickly. Machine perfusion adds a preparation step, circulating oxygenated solution to sustain the organ. In January, the VitaSmart HOPE system received De Novo classification for processing livers after standard cold storage, with FDA setting sterility and perfusion parameters.

Under § 1271.3, vascularized transplant organs fall outside HCT/P regulation. The authors examine a different scenario: complex preparation, significantly longer storage, and functional recovery before transplant. If extended biopreservation becomes clinically viable, physicians deciding organ suitability will need data on preparation, storage, and recovery.

"To make the long-term benefits of advanced biopreservation a reality, legal and ethical oversight tools must be anticipated; this process should begin now." The authors propose quality oversight, specialized storage and recovery centers, data sharing, and allocation rules balancing immediate transplant versus storage. They suggest FDA could clarify whether the HCT/P exclusion applies only to conventional storage, or Congress could act legislatively.

🔗 Read original →
Longevity Market Analysis: Healthmaxxing Goes Mainstream, Transhumanism Still Distant

A new market analysis surveyed 500 U.S. consumers to map the longevity landscape. The dominant trend is "healthmaxxing" — aggressive self-optimization via wearables, blood tests, supplements, AI, and lifestyle changes. The goal: continuous monitoring and preemptive intervention.

Adoption is broad but shallow. 54% use wearables, and 83% of owners check data daily. Yet 55% report no resulting behavior change or doctor visit. Nearly ¾ would wear a second device for new biomarkers. Demand for monitoring is outpacing the ability to translate biometrics into action.

Toxin anxiety drives spending. 63% have heard of microplastics; 35% worry about bodily accumulation. 70% filter water, 39% swap plastic for glass, 24% buy non-toxic cookware, and 62% pay a premium for "non-toxic" labels. The authors note consumer spending is growing faster than scientific proof — often buying peace of mind, not proven risk reduction.

On the pharma front, GLP-1 drugs dominate. Semaglutide and tirzepatide (diabetes/obesity) fuel interest in other peptides marketed for recovery, aesthetics, and performance — many lacking FDA approval or human safety data. The compounded peptide market is worth single-digit billions; tirzepatide generated nearly $30B in its first nine months of 2026 (Mounjaro/Zepbound). A clear gap between biohacking hype and clinical evidence.

Cardiovascular prevention is rising. ~20% have elevated lipoprotein(a) / Lp(a), a hereditary risk factor. U.S. guidelines now recommend one-time adult screening. In one study, adding Repatha to standard care in diabetic patients cut the calculated 5-year risk of first heart attack, stroke, or cardiovascular death by 31%. This shifts longevity from "feeling healthier" to measured risk reduction.

AI is becoming healthcare infrastructure. Companies aim to unify medical records, labs, wearables, prescriptions, and monitoring — so AI schedules the next test, books the specialist, and tracks treatment, not just explains results.

Neurotech is emerging: 39% would use non-invasive devices for sleep, focus, or mood tracking; 29% are interested in brain-computer interfaces.

This is not transhumanism yet. It is "soy longevity" — better maintenance of the existing human chassis: earlier detection, risk reduction, preserved function, delayed aging. Real gains are possible (CVD mortality drops, metabolic treatment), but biology remains the baseline.

This phase may be a necessary precursor. Society is learning to treat health as a managed process: continuous monitoring, personalized medicine, data access, and pre-symptomatic intervention. The next step — radical capability expansion via biotech, neural interfaces, and body modification — builds on this foundation. For transhumanism, this is not the destination, but a potentially useful preparatory stage.

🔗 Read original →
Nectome targets January 2027 for first human brain preservation, raises $3M

Nectome co-founder Aurelia Song announced on the LessWrong forum that the company plans to accept its first human clients in mid-January 2027. The startup has also secured roughly $3 million via Lightcone Commons to study the limits of its preservation method.

Eligible clients must be terminally ill patients able to travel to Portland, Oregon, and consent to medical aid in dying (MAID). A physician prescribes a lethal drug which the patient self-administers. Song’s protocol requires perfusion to begin while the patient is still alive, but current laws prohibit this; she adapted the method for post-mortem preservation instead.

After cardiac arrest, a team perfuses the body: washing out blood, introducing a fixative to lock cellular structure, and adding a cryoprotectant against ice formation. Three strict conditions apply: the heart must stop quickly (prolonged dying damages the brain), heparin must be given beforehand, and perfusion must start within 12 minutes of circulatory arrest.

The 12-minute window was derived from rat experiments. In a pig study preprint, one pig perfused at 13.8 minutes post-arrest showed near-complete fixation, while two pigs perfused at 18.3 and 22.8 minutes remained largely unpreserved. The authors attribute this to microvascular clotting and constriction after blood flow stops — a mechanism familiar from stroke research.

Song previously hoped for a two-hour window compatible with hospice care. However, her best human case — a donor brain preserved 90 minutes after death — failed validation. Neuroscientist Ken Hayworth, co-founder of the Brain Preservation Foundation, reportedly found that synapses could not be traced to neurons on electron microscopy. Song concluded the hospice model is unviable; scheduled MAID deaths are required.

Song frames the method’s limits with three questions: handling unexpected deaths, accepting hospice patients, and whether the 12-minute perfusion window can be extended. Nectome pitched this research to Lightcone Commons, a grant platform launched in July by Lightcone Infrastructure (operators of LessWrong). Song says Lightcone deemed the project promising and allocated ~$3M for 2027 limit-testing.

The company reports its first paid preservation was performed on a dog with terminal cancer. From March to April, Nectome sold roughly 50 pre-orders totaling $1.3 million. A final "discount card" sale is now open until January 15: $29,000 buys a card whose discount scales with holding time — free preservation after ten years (current full price: $250,000). Only 100 cards are available. Song notes that if a buyer uses the free option in ten years, it will cost the company more than the card revenue — unless costs drop significantly by then.

🔗 Read original →
Senotherapies mapped into six strategies: palbociclib halts tumor and silences inflammation in aged liver

On 13 September 2026, the channel “Immortality Handbook 2.0” proposed an original map of six ways to target senescent cells. Primary sources confirm these approaches, but some describe the biological mechanism while others describe the delivery method. The drug’s place on the map is set by the tissue and the therapeutic goal.

Senescent cells stop dividing and can secrete factors that sustain inflammation. Senolytics kill such cells. Navitoclax blocks BCL-xL — a protein that helps senescent cells survive. The same protein is needed by platelets, so the drug can reduce blood clotting. This toxicity pushed researchers toward more precise elimination: antibodies, nanoparticles, and CAR-T cells — T cells with an artificial receptor. Anti-uPAR CAR-T cells recognize a marker on a subset of senescent cells. In 2026 they improved intestinal regeneration in old mice; this line began in 2020 with a liver fibrosis model.

A 2024 review called senoblockers agents that prevent a cell from entering senescence, and senoreverters agents that return it from that state. Senomorphics act differently: rapamycin and metformin suppress the inflammatory signals of the senescent cell while preserving its division arrest.

In oncology, senescence is also used to restrain tumors. Chemotherapy, radiation, and CDK4/6 inhibitors — drugs that brake cell division — including palbociclib, push tumor cells into a stable division arrest. A 2026 review describes an experimental “one-two punch” scheme: after the first hit, a senolytic or immune tool removes the senescent cells. In the liver of old mice, the same palbociclib suppressed the inflammatory signal of already senescent cells and improved motor coordination.

Ibrutinib shows another role-switching option. The drug is used for chronic lymphocytic leukemia and mantle cell lymphoma; by blocking BTK kinase, it reduces the activity of the p53 protein that triggers senescence. In mice with progeria — a hereditary accelerated aging model — ibrutinib increased maximum lifespan, reduced frailty, and preserved spatial memory.

The term “senoptosis” denotes different processes in a research article and an index thesaurus. In 2017, German biologists named “senoptosis” the path of an irradiated cell into deep senescence: the enzyme EndoG cleaves DNA, but the cell remains alive and no longer divides. In the MeSH 2022 thesaurus, “senoptosis inducers” refer to agents that eliminate senescent cells. Thus one word names both the cell’s entry into senescence and its destruction.

🔗 Read original →
Reality Is Worse Than Cyberpunk

You have: mega-corporations, cultural decay amid technological progress, privacy erosion, and deepening social stratification. So you live in a cyberpunk world? No — you actually have it worse. Every character in that setting also gets body modifications. A cyborg wanders a noir megacity of neon signs with prosthetics, while you count your damn 10,000 steps for a drop of health in a drab European city with ordinary infrastructure. Literally all the worst parts of the genre, and none of the best. A joke, of course, but it makes you wonder how our reality lost to a "dystopian" genre.

🔗 Source: @solid_state_humanity
Compound Boosts DNA Repair in Progeria and Down Syndrome Cells, Extends Mouse Lifespan by 8.6%

On November 1, Nature Communications published a study from Elsa Logarinho's group at the University of Porto. The compound UMK57 enhances the protein KIF2C, which disassembles microtubules — filaments of the cell's internal skeleton. In skin cells from patients, it reduced the number of unrepaired DNA breaks, and in progeria mice it increased median lifespan to 17.1 weeks versus 15.7 weeks in untreated controls.

When both DNA strands break, the cell must bring the severed ends together. In 2024, a University of Toronto group described this process: microtubules indent the nuclear envelope, forming a tubular fold that captures the break so the ends can find each other. These folds require dynamic microtubules — some threads grow while others disassemble, a process driven by KIF2C. A 2020 study showed that without KIF2C, repair weakens, breaks accumulate, and their movement through the nucleus is impaired.

Logarinho's group previously found in 2020 that KIF2C levels are lower in elderly human skin cells, and that UMK57 reduces chromosome segregation errors and slows cellular aging. The new work tested whether the compound repairs DNA even without cell division, using cells from two diseases marked by excess DNA damage and accelerated aging: Hutchinson–Gilford progeria syndrome (caused by an LMNA mutation that distorts nuclear shape) and Down syndrome (trisomy 21).

In cells from both diseases, KIF2C was reduced and microtubules were abnormally stable. UMK57 restored normal microtubule turnover in progeria cells and lowered unrepaired breaks in both conditions. After treatment with the DNA-breaking drug etoposide, the fraction of cells with nuclear folds increased in healthy cells but not in patient cells; with UMK57, folds appeared in patient cells and breaks decreased. In a separate assay, one hour of etoposide caused breaks in most cells of all types, but after 24 hours patient cells repaired them poorly — UMK57 restored repair to near-healthy levels. Misshapen nuclei and senescent cells also decreased.

Dependence on KIF2C was confirmed by two controls. The analog UMK95 — differing by one chemical group and unable to accelerate microtubule disassembly in vitro — had no effect in progeria cells. When KIF2C was nearly eliminated, UMK57 lost its effect; with partial knockdown, the effect persisted. To exclude division-related DNA damage, healthy cells were arrested in G1 phase, damaged with etoposide, and showed fewer breaks with UMK57.

Progeria mice were treated from week 5 to week 13. Because UMK57 has poor solubility and is rapidly degraded by liver enzymes in vitro, it was delivered continuously via subcutaneous pump. Mice were euthanized upon 25% body-weight loss or severe morbidity. Median survival for 16 treated mice was 17.1 weeks versus 15.7 weeks for 14 controls — an 8.6% increase. Treated mice began losing weight later, and nearly 40% of spinal curvature was corrected. All mice eventually developed cachexia.

The authors note that interventions enhancing DNA repair remain rare because repair requires coordinated action of multiple pathways that "cannot be simply boosted by increasing the activity of only one or a few genes." UMK57 acts at the convergence point where broken ends meet: it potentiates KIF2C and, with it, microtubule renewal. Next steps include experiments in Down syndrome mice, compound optimization, and safety testing. Logarinho is listed as an inventor on a patent covering UMK57 applications.

🔗 Read original →
Hinton Pushes FDA-Style AI Regulation; Critics Call It a Death Sentence for Innovation

Geoffrey Hinton, often called the "godfather of AI," recently told the Guardian that AI models should face FDA-style pre-market approval. He argued companies must prove a model does more good than harm before release, citing the thalidomide tragedy as a warning against the "release first, litigate later" approach.

The analogy is flawed. A molecule like thalidomide can be tested for specific chemical reactions in a lab. A general-purpose neural network generates open-ended code and text; its "harm" depends entirely on the prompt a bad actor injects. What specific "safety proof" could Big Tech possibly submit to a hypothetical AI-FDA?

Critics counter that FDA-style regulation is a proven killer. Protocols demanding "absolute safety" stall vital drugs for years — denying dying patients access to experimental therapies is formalized murder disguised as care. Furthermore, regulatory capture is inevitable: giants like OpenAI and Google would use billions to buy compliance, crush open-source, and cement monopoly.

Hinton's pivot from proving neural nets work to demanding bureaucratic strangulation of the field marks a tragic turn. We cannot let this mindset destroy AI progress the way it crippled implants and prosthetics.

🔗 Read original →
Why Injuries Heal Slower at 45 Than 25: Tendon Core Forms by Age 17

Avi Roy, a biomedical researcher, posted a thread on X on November 2 explaining why recovery slows with age. The core of the Achilles tendon barely renews after age 17, muscle stem cells activate later, and the brain's pain inhibition weakens.

Copenhagen scientists used carbon-14 dating (the "bomb pulse" from 1955–1963 nuclear tests) on 28 Achilles tendon samples. Collagen in the tendon core matched atmospheric levels from the first 17 years of life, indicating virtually no turnover in the load-bearing core after growth stops. Muscle tissue from the same donors showed fresh carbon-14, confirming muscle renews.

Roy reconciles this with studies showing ~1% daily collagen synthesis (implying a 2-month half-life): cells produce collagen, but the structural core isn't replaced. Carbon-14 dating also showed knee cartilage collagen forms in school years. A chemical age marker found intervertebral disc collagen half-life is 95 years (ages 20–40) and 215 years (ages 50–80).

Muscle repair relies on satellite cells. After one resistance session, satellite cells in fast fibers exceeded baseline at 48 hours in 22-year-olds vs 72 hours in 73-year-olds. After 2 weeks immobilization + 4 weeks training, men 61–74 regained strength but fiber size and satellite cell count did not increase; men 21–30 showed growth in both.

Pain inhibition declines with age. In Hamburg, 64 volunteers rated forearm heat pain (0–100) while a foot was in ice water. Pain ratings dropped 9.9 points (ages 20–40), 1.7 (41–60), and 1.6 (61–80); only the youngest drop was statistically significant.

Bone is an exception: 33 patients 65+ with femoral neck fractures fixed with rods healed at 94% vs 89% for younger patients, though mobility was worse.

Tendon adapts to load. In a 1-year trial, 33 people (62–70) did heavy, moderate, or no training. Patellar tendon thickened 6% (heavy), 5% (moderate), 1% (control) (borderline significance). Stretch resistance was maintained only with heavy loading; it fell in the other groups. Biopsies showed core collagen content and cross-links unchanged. Authors suggest the outer tendon region responds to loading.

🔗 Read original →
Low DGLA Levels Let Senescent Cells Survive; Supplementation Triggers Ferroptotic Death

A study from Christopher Wiley's lab at Tufts University, published in Cell on November 2, reveals that the fatty acid DGLA (dihomo-gamma-linolenic acid) selectively kills senescent cells via ferroptosis.

Senescent cells accumulate with age and drive inflammation. The choice between senescence and ferroptosis — an iron-dependent form of cell death driven by lipid peroxidation — was previously unclear. Wiley's 2021 work showed senescent cells convert polyunsaturated fatty acids (PUFAs) into signaling lipids that lock in growth arrest. The new study examined what happens to these fatty acids in membranes.

In human senescent fibroblasts, membrane PUFAs increased overall, but DGLA specifically decreased. DGLA sits between FADS2 (which produces it) and FADS1 (which converts it to arachidonic acid). Across five senescence-inducing methods, the enzyme balance shifted toward FADS1, depleting DGLA.

Supplementing DGLA in culture killed senescent cells within three days via ferroptosis, sparing normal cells. Other omega-6/omega-3 fatty acids lacked this selectivity. An FADS1 inhibitor, which blocks DGLA conversion, also selectively killed senescent cells. Ferroptosis inhibitors (iron chelators, lipophilic antioxidants) rescued the cells; blockers of apoptosis or necroptosis did not. DGLA induced ferroptosis earlier in C. elegans and human cancer cells.

Senescent cells actively take up DGLA via the transporter CD36; blocking CD36 prevented death. They exist in a "sub-ferroptotic stress" state — high free iron, elevated lipoxygenase genes, and baseline membrane peroxidation — held in check by elevated GPX4.

In 22–24-month-old mice, five daily DGLA injections reduced senescence markers (β-galactosidase, p21, p16) in fat and liver after two weeks. Inflammatory genes dropped in fat. Male mice showed improved liver and kidney blood markers in cohorts with worse baseline health. Wiley is an inventor on patents for DGLA-based senolysis.

A human cohort in Kuopio, Finland (131 women, 54 men with obesity) found that an FADS1 variant (CC genotype) impairing DGLA-to-arachidonic conversion correlated with lower p21 expression in subcutaneous fat — significant in women and the combined group.

Separately, Paul Robbins' group at the University of Minnesota found conjugated fatty acids (alternating double bonds), not DGLA, induced ferroptosis in mouse senescent cells.

🔗 Read original →
"Three-Parent IVF" Shows Maternal Mitochondrial Reversion in Children

STAT compiled data from clinics in Greece, the UK, and Ukraine revealing that maternal mitochondria — which the technique aims to replace — have reappeared in several children born via mitochondrial replacement therapy (MRT).

Mitochondria carry their own DNA, inherited maternally; mutations cause severe diseases. MRT transfers the nuclear DNA from a mother's egg or embryo into a donor egg with healthy mitochondria. However, trace maternal mitochondria tag along with the nucleus. In 2016, Shoukhrat Mitalipov's group showed that while donor DNA exceeded 99% in embryos, it gradually lost ground to maternal DNA in derived stem cell lines, a phenomenon dubbed "reversion."

In the Greek infertility trial, one of six children saw maternal mitochondria rise from <1% in the embryo to 30–60% at birth. In Newcastle, UK, where MRT treats mitochondrial disease, three of eight children showed 5%, 12%, and 16% mutant maternal mitochondria in blood. Ukraine's Nadiya clinic provided unpublished data: two of six children exhibited reversion up to 12% and 72%.

Embryologist Jacques Cohen argues reversion is less concerning for infertility — where mothers lack pathogenic mutations — but urges a moratorium for mitochondrial disease until reversion risk is minimized. Bioethicist Guido Pennings proposes testing first in infertile couples without mutations to study reversion safely.

STAT found clinics marketing MRT to older women, claiming young mitochondria aid development. Nadiya embryologist Pavel Mazur transferred nuclei from 19 women aged 36–44 into young donor eggs; only one yielded a chromosomally normal embryo. Conversely, transferring young donor nuclei into patient eggs yielded 40% usable embryos with 70% normal chromosomes — suggesting nuclear DNA damage, not mitochondrial age, drives failure.

In Ghent, Dominik Stoop sought approval for three patient groups. Belgian authorities approved two: mitochondrial disease and oocyte/embryo maturation arrest. The third — advanced maternal age — was rejected. Stoop noted the disease group, seen as least ethically problematic, may be the riskiest.

Mary Herbert (Monash University, formerly Newcastle) cites clinical data showing pathogenic transmission dropped 75–100%, with mutant loads staying below the 50% symptom threshold. Her Australian team is preparing a trial to track mutant load stability over time and across tissues. STAT, November 3

🔗 Read original →
Castrating Adult Male Mice Extends Lifespan More Than Pre-Pubertal Castration (Preprint)

James Nelson's group at the University of Texas Health San Antonio castrated male mice at 20 days (pre-puberty), 60 days (post-puberty), and 240 days (adulthood). Median lifespan reached 841, 887, and 937 days respectively, versus 705 days for sham-operated controls. The preprint appeared on bioRxiv, Oct 24, 2026; a Science news piece followed on Nov 2.

Men live shorter lives than women almost everywhere; in the US in 2024 the gap was 4.9 years. Testes are a prime suspect: a Korean genealogy of 81 eunuchs showed they lived 14–19 years longer than intact men of similar status, though another researcher disputed the records' reliability. In genetically heterogeneous UM-HET3 mice, females consistently outlive males. In a 2023 experiment, Nelson's group castrated such males pre-puberty, raising median lifespan from 771 to 850 days, matching females. The remaining question: from what age do testicular factors — hormones and other secretions — cause harm?

If the pubertal hormone surge sets the damage, surgery at 60 days (after puberty) would be too late; if harm accumulates from youth, surgery at 240 days (before male mortality rises) would be too late. Controls lived shorter than in past studies: median 705 days vs 771. The authors note this may inflate percentage gains: castration at 240 days added 32.9% to 705 days, but only 21.5% to 771. Surgery at 60 days did not differ significantly from 20 days; the authors conclude the pubertal hormone surge does not shorten male life.

From roughly 240 days, mortality in intact males rises, and surgery at this age halted that rise immediately: on the preprint's survival curve, no mouse in this group died for about a year post-operation. Surgery at 240 days worked, so testicular factors act fast, and elevated male mortality depends on their continuous presence. Mice retaining testes until 240 days died less often in late life than those castrated at 20 days, suggesting testes may be beneficial before 240 days. The authors checked for a "reserve" of resilience, but grip strength and frailty indices were no better than in earlier-castrated mice.

A zoo-data analysis in Nature found pre-pubertal castration extended life more than later castration; the preprint authors say their data contradict the "earlier is better" model. The first author of that analysis, Michael Garratt (University of Otago), uninvolved in the mouse study, commented: "I am convinced that late-life castration causes a robust increase in survival." If harmful testicular factors are identified, "castration mimetics" — interventions giving the same lifespan gain without surgery — become possible. Since surgery helps at 240 days, the authors estimate these factors can be blocked in adulthood, preserving any early-life benefit.

Per a review by Nelson's group, 11 of 13 lifespan-extending compounds in the ITP program show stronger effects in males or work only in males. The preprint authors speculate some may suppress testicular harm, and propose testing compounds in males with and without testes to find those acting via testicular factors.

🔗 Read original →
Revel Pharmaceuticals Co-Founder Chooses Enzymatic Protein Repair Over Cellular Reprogramming

Aaron Cravens explained on the November 3 Free Radicals podcast how Revel selects damage targets for repair and why he believes cellular reprogramming — the attempt to revert cells to a youthful state — faces a fundamental delivery barrier.

Collagen and other structural proteins persist for decades while surrounding cells turnover, accumulating chemical damage. Cravens calls this "rust" and selects targets by asking: "What is in old tissue that isn't in young tissue? And if it's in old tissue and not in young tissue — not counting wisdom — we want to get rid of it." His hypothesis: removing all damage distinguishing old from young should restore a youthful state.

Revel largely ignores cellular biology as too complex. Damage has known chemical structures and accumulates linearly with age, whereas senescent cells exist even in the young. Cravens cites the cautionary example of senolytics: senescent cells may be needed for wound healing. Reprogramming, he argues, hits a delivery wall: rejuvenating fibroblasts requires reaching over 90% of them, but delivering DNA-based technologies is difficult.

Revel's first target is carboxymethyllysine (CML), a lysine modified by reactions with sugars and fats. Known for ~40 years, Cravens expected success within six years. CML blocks collagen lysines used for cell binding and triggers systemic inflammation in mice. In humans, CML correlates with mortality: an Italian study of 1,013 people over 65 found the top tertile of plasma CML had a 2.1x higher risk of cardiovascular death over six years (Nature Communications, July 14).

Cravens posits that regeneration weakens because damage has "rusted it in place." Reprogramming proponents hope engineered cells will restore this capacity. Instead, Revel mimics lysosomal storage disease therapy: supplying missing enzymes to clear accumulated waste. For damage accumulating over decades, the body lacks enzymes because evolution didn't require post-reproductive longevity.

On July 14, Revel published in Nature Communications on CMLase, an engineered bacterial enzyme. It converted CML back to lysine: on donor tissue slices, CML staining dropped >70% in a 75-year-old's aorta and >55% in a 74-year-old's skin, reaching levels below a 31-year-old's skin. Cravens aims to apply CMLase first for diabetic retinopathy, kidney disease, and skin aging, hoping for topical use within a year. He plans 4–6 drugs against different damage types and envisions synergy with reprogramming if a working cocktail emerges.

🔗 Read original →
George Murphy Parses First ER-100 Gene Therapy Data: Vision Benefit, Tissue Rejuvenation, and Healthspan Extension Require Different Evidence

On November 2, George Murphy, co-founder of the Boston University Center for Regenerative Medicine, analyzed the initial ER-100 data on The ReProgram podcast. This gene therapy transiently induces retinal cells to produce three proteins to restore a more youthful gene expression pattern.

On October 8, Life Biosciences reported that in a Phase 1 safety trial, two of three glaucoma patients showed improved visual field test results at 56 days. Murphy sees grounds for further study. If future trials confirm sustained vision improvement, he argues for distinguishing three claims.

First, clinical benefit: the patient sees better or loses vision more slowly. Second, tissue rejuvenation: this requires linking the intervention, biological changes, and improved tissue function, since protection, compensation, or better function of surviving cells could also drive improvement. Glaucoma specialist James Tsai, uninvolved in the trial, raised a similar point in Business Insider: the therapy may have merely enhanced existing electrical signals in patients with residual vision.

Third, healthspan extension: the heart, immune system, and brain pose distinct delivery challenges, biology, endpoints, and risks, demanding separate, larger studies.

The visual field test maps light sensitivity: the patient fixates centrally while the device detects the dimmest visible flash at each point (threshold in decibels). The release states that for each of the two responders, at least 28% of test points improved by more than 4 decibels.

Murphy highlights alternative explanations. Practice effects are documented in glaucoma suspects; a randomly low baseline makes the next test appear better without treatment. The registry lists the trial as open-label — clinicians and participants know the treatment assignment — and expectations can influence responses on an attention-dependent test. Each participant is compared to their own baseline. With many test points and visits, some improvements may be chance findings. Points within one eye belong to a single biological system: "Several improved test points in one eye do not equal several independent patients."

Other endpoints recorded in the registry at Day 56 and Day 112 — such as visual acuity (letter reading) and retinal electrical response — could corroborate the field improvement. Doxycycline, taken for 56 days, activates protein production; the Day 112 measurement will show whether improvement persists after shutdown. Murphy notes: "Turning off production of a biological factor and reversing what it has already changed are different tasks."

For Murphy, a useful therapy makes tissue better at its job with acceptable, durable safety; molecular analyses showing a "younger" tissue state may only help explain the result. He wants longitudinal per-participant data; comparison with a control group and independent adjudication; benefit noticeable to the patient; and replication in larger, multi-center cohorts. In his episode description he writes: "A treatment can be a major medical advance without proving that aging has been reversed."

🔗 Read original →
Tiny Magnetic Beads Enable Precise Bionic Limb Control

A new technique called magnetomicrometry uses tiny magnetic beads implanted directly into muscle tissue to control bionic prostheses. This bypasses the limitations of surface electrodes, which suffer from signal noise, sweat interference, and signal decay over time.

Researchers implanted up to four pairs of 3-millimeter beads — made from a neodymium-iron-boron alloy and coated in gold and biocompatible Parylene C — into the ankle muscles of three below-knee amputees. External sensors tracked the beads' magnetic fields through up to 6 centimeters of tissue, measuring physical distance changes during muscle contraction and extension.

Participants controlled a virtual cursor using muscle effort, allowing direct comparison of surface EMG, implanted electrodes, and magnetomicrometry. The magnetic approach delivered significantly more stable, cleaner, and precise control because it measures actual mechanical movement rather than noisy electrical activity.

The team is now advancing to expanded clinical trials to test the implants within full robotic leg prostheses. Science Robotics, July 2024

🔗 Read original →